Request Free Sample ×
India Biopharmaceuticals Market Research Report - Forecast to 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

India Biopharmaceuticals Market

ID: MRFR/MED/49461-HCR
200 Pages
Nidhi Mandole
Last Updated: February 06, 2026

India Biopharmaceuticals Market Research Report: Size, Share, Trend Analysis By Product Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cellular Therapies), By Applications (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases), By End Use (Hospitals, Biotechnology Companies, Pharmaceutical Companies) and By Route of Administration (Intravenous, Subcutaneous, Intramuscular) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

India Biopharmaceuticals Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Construction, BY Product Type (USD Billion)
  49.     4.1.1 Monoclonal Antibodies
  50.     4.1.2 Recombinant Proteins
  51.     4.1.3 Vaccines
  52.     4.1.4 Cellular Therapies
  53.   4.2 Construction, BY Application (USD Billion)
  54.     4.2.1 Oncology
  55.     4.2.2 Autoimmune Diseases
  56.     4.2.3 Infectious Diseases
  57.     4.2.4 Cardiovascular Diseases
  58.   4.3 Construction, BY End-use (USD Billion)
  59.     4.3.1 Hospitals
  60.     4.3.2 Biotechnology Companies
  61.     4.3.3 Pharmaceutical Companies
  62.   4.4 Construction, BY Route of Administration (USD Billion)
  63.     4.4.1 Intravenous
  64.     4.4.2 Subcutaneous
  65.     4.4.3 Intramuscular
  66. 5 SECTION V: COMPETITIVE ANALYSIS
  67.   5.1 Competitive Landscape
  68.     5.1.1 Overview
  69.     5.1.2 Competitive Analysis
  70.     5.1.3 Market share Analysis
  71.     5.1.4 Major Growth Strategy in the Construction
  72.     5.1.5 Competitive Benchmarking
  73.     5.1.6 Leading Players in Terms of Number of Developments in the Construction
  74.     5.1.7 Key developments and growth strategies
  75.       5.1.7.1 New Product Launch/Service Deployment
  76.       5.1.7.2 Merger & Acquisitions
  77.       5.1.7.3 Joint Ventures
  78.     5.1.8 Major Players Financial Matrix
  79.       5.1.8.1 Sales and Operating Income
  80.       5.1.8.2 Major Players R&D Expenditure. 2023
  81.   5.2 Company Profiles
  82.     5.2.1 AbbVie (US)
  83.       5.2.1.1 Financial Overview
  84.       5.2.1.2 Products Offered
  85.       5.2.1.3 Key Developments
  86.       5.2.1.4 SWOT Analysis
  87.       5.2.1.5 Key Strategies
  88.     5.2.2 Amgen (US)
  89.       5.2.2.1 Financial Overview
  90.       5.2.2.2 Products Offered
  91.       5.2.2.3 Key Developments
  92.       5.2.2.4 SWOT Analysis
  93.       5.2.2.5 Key Strategies
  94.     5.2.3 Bristol-Myers Squibb (US)
  95.       5.2.3.1 Financial Overview
  96.       5.2.3.2 Products Offered
  97.       5.2.3.3 Key Developments
  98.       5.2.3.4 SWOT Analysis
  99.       5.2.3.5 Key Strategies
  100.     5.2.4 Gilead Sciences (US)
  101.       5.2.4.1 Financial Overview
  102.       5.2.4.2 Products Offered
  103.       5.2.4.3 Key Developments
  104.       5.2.4.4 SWOT Analysis
  105.       5.2.4.5 Key Strategies
  106.     5.2.5 Johnson & Johnson (US)
  107.       5.2.5.1 Financial Overview
  108.       5.2.5.2 Products Offered
  109.       5.2.5.3 Key Developments
  110.       5.2.5.4 SWOT Analysis
  111.       5.2.5.5 Key Strategies
  112.     5.2.6 Merck & Co. (US)
  113.       5.2.6.1 Financial Overview
  114.       5.2.6.2 Products Offered
  115.       5.2.6.3 Key Developments
  116.       5.2.6.4 SWOT Analysis
  117.       5.2.6.5 Key Strategies
  118.     5.2.7 Novartis (CH)
  119.       5.2.7.1 Financial Overview
  120.       5.2.7.2 Products Offered
  121.       5.2.7.3 Key Developments
  122.       5.2.7.4 SWOT Analysis
  123.       5.2.7.5 Key Strategies
  124.     5.2.8 Roche (CH)
  125.       5.2.8.1 Financial Overview
  126.       5.2.8.2 Products Offered
  127.       5.2.8.3 Key Developments
  128.       5.2.8.4 SWOT Analysis
  129.       5.2.8.5 Key Strategies
  130.     5.2.9 Sanofi (FR)
  131.       5.2.9.1 Financial Overview
  132.       5.2.9.2 Products Offered
  133.       5.2.9.3 Key Developments
  134.       5.2.9.4 SWOT Analysis
  135.       5.2.9.5 Key Strategies
  136.     5.2.10 Takeda Pharmaceutical (JP)
  137.       5.2.10.1 Financial Overview
  138.       5.2.10.2 Products Offered
  139.       5.2.10.3 Key Developments
  140.       5.2.10.4 SWOT Analysis
  141.       5.2.10.5 Key Strategies
  142.   5.3 Appendix
  143.     5.3.1 References
  144.     5.3.2 Related Reports
  145. 6 LIST OF FIGURES
  146.   6.1 MARKET SYNOPSIS
  147.   6.2 INDIA MARKET ANALYSIS BY PRODUCT TYPE
  148.   6.3 INDIA MARKET ANALYSIS BY APPLICATION
  149.   6.4 INDIA MARKET ANALYSIS BY END-USE
  150.   6.5 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  151.   6.6 KEY BUYING CRITERIA OF CONSTRUCTION
  152.   6.7 RESEARCH PROCESS OF MRFR
  153.   6.8 DRO ANALYSIS OF CONSTRUCTION
  154.   6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
  155.   6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
  156.   6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
  157.   6.12 CONSTRUCTION, BY PRODUCT TYPE, 2024 (% SHARE)
  158.   6.13 CONSTRUCTION, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
  159.   6.14 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
  160.   6.15 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Billion)
  161.   6.16 CONSTRUCTION, BY END-USE, 2024 (% SHARE)
  162.   6.17 CONSTRUCTION, BY END-USE, 2024 TO 2035 (USD Billion)
  163.   6.18 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  164.   6.19 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  165.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  166. 7 LIST OF TABLES
  167.   7.1 LIST OF ASSUMPTIONS
  168.     7.1.1
  169.   7.2 India MARKET SIZE ESTIMATES; FORECAST
  170.     7.2.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  171.     7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
  172.     7.2.3 BY END-USE, 2025-2035 (USD Billion)
  173.     7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  174.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  175.     7.3.1
  176.   7.4 ACQUISITION/PARTNERSHIP
  177.     7.4.1

India Construction Market Segmentation

Construction By Product Type (USD Billion, 2025-2035)

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Cellular Therapies

Construction By Application (USD Billion, 2025-2035)

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases

Construction By End-use (USD Billion, 2025-2035)

  • Hospitals
  • Biotechnology Companies
  • Pharmaceutical Companies

Construction By Route of Administration (USD Billion, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Intramuscular

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓